Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Research & Development (2020 - 2023)

Cullinan Therapeutics has reported Research & Development over the past 4 years, most recently at $34.8 million for Q4 2023.

  • Quarterly results put Research & Development at $34.8 million for Q4 2023, up 63.44% from a year ago — trailing twelve months through Dec 2023 was $148.2 million (up 61.13% YoY), and the annual figure for FY2025 was $187.4 million, up 31.14%.
  • Research & Development for Q4 2023 was $34.8 million at Cullinan Therapeutics, up from $33.8 million in the prior quarter.
  • Over the last five years, Research & Development for CGEM hit a ceiling of $52.1 million in Q1 2023 and a floor of $4.2 million in Q1 2020.
  • Median Research & Development over the past 4 years was $20.3 million (2021), compared with a mean of $21.3 million.
  • Peak annual rise in Research & Development hit 197.51% in 2021, while the deepest fall reached 5.75% in 2021.
  • Cullinan Therapeutics' Research & Development stood at $16.6 million in 2020, then grew by 25.55% to $20.9 million in 2021, then increased by 2.12% to $21.3 million in 2022, then soared by 63.44% to $34.8 million in 2023.
  • The last three reported values for Research & Development were $34.8 million (Q4 2023), $33.8 million (Q3 2023), and $27.4 million (Q2 2023) per Business Quant data.